DRUG · Unmapped registry intervention
Adebrelimab+Dalpciclib+Standard Endocrine Therapy
Find medicine records ·
Find other trials using this name
Clinical trial
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer
NCT06599216
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedAdebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
HR+/HER2- Breast Cancerunresolved
Interventions
Sponsors & collaborators
Harbin Medical Universitylead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06599216 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.